All In Biotech

Drug Trial Radar · NCT07557251

A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma

An Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Participants With Advanced Hepatitis B Virus Related Hepatocellular Carcinoma

Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

21

Planned (sponsor's estimate)

Start

Aug 12, 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Sponsor type
Academic, hospital or other
First posted
Apr 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This early phase (Phase 1) study will evaluate BRII 5395, administered in combination with two approved anticancer agents, sintilimab and bevacizumab, in patients with advanced liver cancer caused by chronic hepatitis B virus (HBV) infection. The primary objective of the study is to assess the safety and tolerability of the combination therapy, as well as to explore preliminary evidence of clinical benefit.

Conditions

  • Advanced HBV-Related Hepatocellular Carcinoma

Interventions

  • BRII-5395Drug

    BRII-5395 will be given via IM injection

  • SintilimabDrug

    Sintilimab will be given via IV infusion

  • BevacizumabDrug

    Bevacizumab will be given via IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and type of dose-limiting toxicities (DLTs)Time frame: Up to 30 days post last dose
  2. Adverse events (AEs) and serious AEs (SAEs)Time frame: Up to 30 days post last dose
  3. Abnormalities in laboratory and other clinical assessmentsTime frame: Up to 30 days post last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.